DSM‘s continuing business’ sales were slightly higher (+1% to €1,913m) as a +5% volume increase was absorbed by a weaker price/mix (-3%) and adverse FX developments (-2%). EBITDA improved +20% to €271m, driven by all divisions. Net profit attributable to shareholders swung from €-70m to €84m. Despite slightly higher NWC outflow, operating CF ramped up from €22m to €137 helped by other items. Stripping out discontinued operations, operating CF was &eur
26 Apr 2016
On the mend?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
On the mend?
- Published:
26 Apr 2016 -
Author:
Martin Schnee -
Pages:
2
DSM‘s continuing business’ sales were slightly higher (+1% to €1,913m) as a +5% volume increase was absorbed by a weaker price/mix (-3%) and adverse FX developments (-2%). EBITDA improved +20% to €271m, driven by all divisions. Net profit attributable to shareholders swung from €-70m to €84m. Despite slightly higher NWC outflow, operating CF ramped up from €22m to €137 helped by other items. Stripping out discontinued operations, operating CF was &eur